KR102820822B1 - B-raf 키나제 억제제의 결정성 염 - Google Patents

B-raf 키나제 억제제의 결정성 염 Download PDF

Info

Publication number
KR102820822B1
KR102820822B1 KR1020207014962A KR20207014962A KR102820822B1 KR 102820822 B1 KR102820822 B1 KR 102820822B1 KR 1020207014962 A KR1020207014962 A KR 1020207014962A KR 20207014962 A KR20207014962 A KR 20207014962A KR 102820822 B1 KR102820822 B1 KR 102820822B1
Authority
KR
South Korea
Prior art keywords
salt
cancer
pyridin
pyrrolo
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020207014962A
Other languages
English (en)
Korean (ko)
Other versions
KR20200088345A (ko
Inventor
울리케 베르트만
게르트-미카엘 마이어
보도 베트체마이어
오트마르 샤프
Original Assignee
자이노믹 파마슈티컬스 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 자이노믹 파마슈티컬스 인코포레이티드 filed Critical 자이노믹 파마슈티컬스 인코포레이티드
Publication of KR20200088345A publication Critical patent/KR20200088345A/ko
Application granted granted Critical
Publication of KR102820822B1 publication Critical patent/KR102820822B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020207014962A 2017-10-26 2018-10-26 B-raf 키나제 억제제의 결정성 염 Active KR102820822B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762577313P 2017-10-26 2017-10-26
US62/577,313 2017-10-26
PCT/US2018/057792 WO2019084459A1 (en) 2017-10-26 2018-10-26 CRYSTALLINE SALTS AND FORMS OF B-RAF KINASE INHIBITOR

Publications (2)

Publication Number Publication Date
KR20200088345A KR20200088345A (ko) 2020-07-22
KR102820822B1 true KR102820822B1 (ko) 2025-06-16

Family

ID=64277870

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207014962A Active KR102820822B1 (ko) 2017-10-26 2018-10-26 B-raf 키나제 억제제의 결정성 염

Country Status (15)

Country Link
US (2) US11306086B2 (https=)
EP (2) EP4245758A3 (https=)
JP (2) JP7230041B2 (https=)
KR (1) KR102820822B1 (https=)
CN (2) CN111818924B (https=)
AU (2) AU2018355528B2 (https=)
BR (1) BR112020008248A2 (https=)
CA (1) CA3080324A1 (https=)
ES (1) ES2947411T3 (https=)
IL (1) IL274027B2 (https=)
MX (1) MX2020004148A (https=)
MY (1) MY203853A (https=)
PH (1) PH12020550485A1 (https=)
SG (1) SG11202003635TA (https=)
WO (1) WO2019084459A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202003635TA (en) 2017-10-26 2020-05-28 Xynomic Pharmaceuticals Inc Crystalline salts of a b-raf kinase inhibitor
JP2022069426A (ja) * 2020-10-23 2022-05-11 マイラン ラボラトリーズ リミテッド テネリグリプチン２．５臭化水素酸塩のアモルファスを調製する方法
TW202508595A (zh) 2023-05-04 2025-03-01 美商銳新醫藥公司 用於ｒａｓ相關疾病或病症之組合療法
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
TW202547461A (zh) 2024-05-17 2025-12-16 美商銳新醫藥公司 Ｒａｓ抑制劑
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012104388A1 (en) 2011-02-02 2012-08-09 Boehringer Ingelheim International Gmbh New azaindolylphenyl sulfonamides as serine/threonine kinase inhibitors

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040127470A1 (en) * 1998-12-23 2004-07-01 Pharmacia Corporation Methods and compositions for the prevention or treatment of neoplasia comprising a Cox-2 inhibitor in combination with an epidermal growth factor receptor antagonist
KR100786927B1 (ko) 2000-06-28 2007-12-17 스미스클라인비이참피이엘시이 습식 분쇄방법
CA2546192C (en) * 2003-11-17 2010-04-06 Pfizer Products Inc. Pyrrolopyrimidine compounds useful in treatment of cancer
GB0423554D0 (en) * 2004-10-22 2004-11-24 Cancer Rec Tech Ltd Therapeutic compounds
UA95244C2 (ru) 2005-06-22 2011-07-25 Плексикон, Инк. Соединения и способ модулирования активности киназ, и показания для их применения
WO2007123892A2 (en) * 2006-04-17 2007-11-01 Arqule Inc. Raf inhibitors and their uses
EP1914234A1 (en) * 2006-10-16 2008-04-23 GPC Biotech Inc. Pyrido[2,3-d]pyrimidines and their use as kinase inhibitors
US20110183975A1 (en) 2008-10-07 2011-07-28 Yasuhiro Goto Novel 6-azaindole aminopyrimidine derivatives having nik inhibitory activity
MY160064A (en) * 2009-09-28 2017-02-15 Hoffmann La Roche Benzoxazepin pi3k inhibitor compounds and methods of use
JP6263469B2 (ja) 2011-07-15 2018-01-17 ノバルティス アーゲー アザ二環式ジ−アリールエーテルの塩およびその製造方法またはその前駆体の製造方法
PL2945628T3 (pl) * 2013-01-15 2020-09-21 Aragon Pharmaceuticals, Inc. Modulator receptorów androgenowych w skojarzeniu z octanem abirateronu i prednizonem do leczenia nowotworu stercza
WO2015095842A2 (en) * 2013-12-20 2015-06-25 Biomed Valley Discoveries, Inc. Methods and compositions for treating non-erk mapk pathway inhibitor-resistant cancers
CN116271056A (zh) 2015-04-16 2023-06-23 日东电工株式会社 针对具有braf基因突变的细胞的细胞死亡诱导试剂、该细胞的增殖抑制试剂及用于治疗由该细胞的增殖异常导致的疾病的医药组合物
CN105801584B (zh) * 2016-03-16 2019-03-05 中国药科大学 新型芳酰胺类Raf激酶抑制剂及其制备方法和用途
SG11202003635TA (en) 2017-10-26 2020-05-28 Xynomic Pharmaceuticals Inc Crystalline salts of a b-raf kinase inhibitor

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012104388A1 (en) 2011-02-02 2012-08-09 Boehringer Ingelheim International Gmbh New azaindolylphenyl sulfonamides as serine/threonine kinase inhibitors

Also Published As

Publication number Publication date
RU2020116763A (ru) 2021-11-26
AU2018355528B2 (en) 2021-11-18
KR20200088345A (ko) 2020-07-22
AU2022201044B2 (en) 2023-07-13
CN116942672A (zh) 2023-10-27
JP2021501199A (ja) 2021-01-14
US11306086B2 (en) 2022-04-19
JP2023062074A (ja) 2023-05-02
CN116942672B (zh) 2026-04-14
IL274027B2 (en) 2023-12-01
MY203853A (en) 2024-07-22
US20220204506A1 (en) 2022-06-30
EP4245758A3 (en) 2023-12-20
IL274027B1 (en) 2023-08-01
CN111818924A (zh) 2020-10-23
ES2947411T3 (es) 2023-08-08
EP3700530B1 (en) 2023-04-19
US11753409B2 (en) 2023-09-12
CN111818924B (zh) 2023-08-15
WO2019084459A1 (en) 2019-05-02
EP3700530A1 (en) 2020-09-02
BR112020008248A2 (pt) 2020-10-20
RU2020116763A3 (https=) 2022-04-29
IL274027A (en) 2020-06-30
MX2020004148A (es) 2022-09-09
SG11202003635TA (en) 2020-05-28
AU2018355528A1 (en) 2020-05-07
PH12020550485A1 (en) 2021-03-22
US20200283433A1 (en) 2020-09-10
JP7230041B2 (ja) 2023-02-28
AU2022201044A1 (en) 2022-03-10
CA3080324A1 (en) 2019-05-02
EP4245758A2 (en) 2023-09-20

Similar Documents

Publication Publication Date Title
KR102820822B1 (ko) B-raf 키나제 억제제의 결정성 염
USRE50594E1 (en) Spiro[3H-indole-3,2′-pyrrolidin]-2(1H)-one compounds and derivatives as MDM2-P53 inhibitors
ES2739697T3 (es) Nuevos compuestos y derivados de espiro[3H-indol-3,2-pirrolidin]-2(1H)-ona como inhibidores de MDM2-p53
WO2016001376A1 (en) New spiro[3h-indole-3,2´-pyrrolidin]-2(1h)-one compounds and derivatives as mdm2-p53 inhibitors
RU2798091C2 (ru) Кристаллические соли ингибитора b-raf-киназы
HK40098127A (en) Crystalline salts of a b-raf kinase inhibitor
HK40035621B (en) Crystalline salts of a b-raf kinase inhibitor
HK40035621A (en) Crystalline salts of a b-raf kinase inhibitor
HK1252365B (en) Spiro[3h-indole-3,2’-pyrrolidin]-2(1h)-one compounds and derivatives as mdm2-p53 inhibitors

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20200525

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20211025

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20231205

Patent event code: PE09021S01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20240817

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20250324

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20250611

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20250612

End annual number: 3

Start annual number: 1

PG1601 Publication of registration